RE: Interesting15 Jan 2025 14:40
CJ39
“ There is a lot of buying, is news imminent with Stalicla? Nothing has changed on their website.”
The “news” is in every peer-reviewed publication by the academics who work with them.
As for Stalicla, they are progressing with Phase 2 trials using SFX001. They need TCF to supply the drug, otherwise, er, there will be no Phase 2 trial!!
Lynn Durham, founder and ceo of Stalicla, is definitely at one end of some kind of spectrum. She is super articulate in both English and French. It wouldn’t surprise me in the least, to learn that she is fluent in German and Italian also. On the other hand, I can imagine her arguing that the SFX001 deal was for a Phase 2 for disorder A1, but they will now use it for disorder B2, so they don’t owe money to TCF. Meh, maybe I’m overthinking that, but they definitely need the enteric coated capsules for drug delivery.
Otherwise no Phase 2 trials.
As she said in a panel discussion of fundraisers last year, Big Pharma has Hot Money for behavioural drugs.